当前位置:首页 - 行情中心 - 康泰生物(300601) - 财务分析 - 利润表

康泰生物

(300601)

  

流通市值:207.94亿  总市值:265.38亿
流通股本:8.75亿   总股本:11.17亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入2,464,464,778.621,730,568,886.34748,383,301.393,157,401,754.79
营业收入2,464,464,778.621,730,568,886.34748,383,301.393,157,401,754.79
二、营业总成本1,732,477,412.921,180,899,409.01502,644,829.282,617,680,291.59
营业成本343,813,848.59229,384,352.18105,437,431.28499,947,447.95
税金及附加15,190,520.2911,590,682.264,170,169.4520,491,956.37
销售费用845,517,600.1596,436,582.05259,204,013.181,086,360,342.33
管理费用171,346,770.77100,048,292.7351,650,868.48230,178,371.64
研发费用358,500,265.94244,805,451.0384,466,623.59801,856,715.59
财务费用-1,891,592.77-1,365,951.24-2,284,276.7-21,154,542.29
其中:利息费用83,884,771.8155,511,776.8727,481,440.96108,972,175.65
其中:利息收入86,041,754.2156,932,272.9929,811,258.7132,624,829.12
加:公允价值变动收益120,990.5724,410.38-3,176,868.23
加:投资收益1,698,159.771,698,159.771,466,592.11944,049.37
资产处置收益-499,776.9874,778.74-127,433.95
资产减值损失(新)-44,032,862.85-43,170,770.68-8,695,078.99-896,493,014.32
信用减值损失(新)-38,825,250.04-37,524,832.32-13,726,239.46-39,484,097.27
其他收益118,300,646.9294,785,194.719,563,457.1174,436,297.08
营业利润平衡项目0000
四、营业利润768,749,273.17566,356,417.92244,347,202.88-317,570,999.76
加:营业外收入538,800.09378,045.6192,004.36,613,063.38
减:营业外支出4,285,571.662,973,961.662,721,147.9227,288,526.01
利润总额平衡项目0000
五、利润总额765,002,501.6563,760,501.86241,818,059.26-338,246,462.39
减:所得税费用67,951,637.1253,328,984.5136,355,239.01-205,538,603.1
六、净利润697,050,864.48510,431,517.35205,462,820.25-132,707,859.29
持续经营净利润697,050,864.48510,431,517.35205,462,820.25-132,707,859.29
归属于母公司股东的净利润697,050,864.48510,431,517.35205,462,820.25-132,707,859.29
(一)基本每股收益0.620.460.18-0.12
(二)稀释每股收益0.620.460.18-0.12
九、综合收益总额697,050,864.48510,431,517.35205,462,820.25-132,707,859.29
归属于母公司股东的综合收益总额697,050,864.48510,431,517.35205,462,820.25-132,707,859.29
公告日期2023-10-272023-08-262023-04-242023-04-24
审计意见(境内)标准无保留意见
TOP↑